Analysis in progress
Initialising…
0%
complete
This report is still being assembled — sections appear as each stage finishes. It isn't final yet.
MSH2
Final classification
VUS
MSH2 c.1132del · p.Glu378LysfsTer34
MSH2

PVS1 at Very Strong strength: NM_000251.3:c.1132del is a frameshift deletion in exon 7 of MSH2 introducing a premature termination codon at codon 411 (p.Glu378LysfsTer34), which is ≤ codon 891, meeting the InSiGHT MSH2 VCEP v2.0.0 PVS1 Very Strong rule for null variants.

Gene
MSH2
Transcript
NM_000251.3
HGVS · transcript:coding
NM_000251.3:c.1132del
Consequence
N/A
GRCh38
chr2:47429796 AG>A
GRCh37
chr2:47656935 AG>A
Basis Richards et.al., 2015 - Combining rules v2.0.0 criteria-combination framework was evaluated deterministically with applied criteria: PVS1 very strong, PM2 supporting; no rule matched the adjudicated criteria.
Richards et.al., 2015 - Combining rules v2.0.0 criteria-combination framework was evaluated deterministically with applied criteria: PVS1 very strong, PM2 supporting; no rule matched the adjudicated criteria.
Classification rationale
PVS1PM2 VUS
MSH2 c.1132del

PVS1 at Very Strong strength: NM_000251.3:c.1132del is a frameshift deletion in exon 7 of MSH2 introducing a premature termination codon at codon 411 (p.Glu378LysfsTer34), which is ≤ codon 891, meeting the InSiGHT MSH2 VCEP v2.0.0 PVS1 Very Strong rule for null variants.1 PM2 at Supporting strength: the variant is absent from gnomAD-Canada v1.0 and absent from ClinVar, consistent with extreme rarity in the general population. gnomAD v4.1 frequency data were not retrieved; human review recommended to confirm PM2 status against the VCEP threshold of <0.00002.2

PVS1 + PM2 VUS
Gene diagram · NM_000251.3 · variants mapped to exon structure
MSH2 NM_000251.3
Fetching transcript structure from UCSC…
Applied criteria · 2 applied · 8 assessed
Applied · 2
Strength Supporting Moderate Strong Very strong
PVS1 very strong Pathogenic
NM_000251.3:c.1132del is a frameshift deletion in exon 7 of MSH2, predicted to introduce a premature termination codon at codon 411 (p.Glu378LysfsTer34). Under the InSiGHT MSH2 VCEP v2.0.0 PVS1 rule, nonsense/frameshift variants introducing a PTC ≤ codon 891 qualify for PVS1 at Very Strong strength. Codon 411 is well below this threshold.
Frameshift deletion in exon 7 introducing PTC at codon 411 (≤891)InSiGHT MSH2 VCEP v2.0.0 PVS1 rule: PTC ≤ codon 891 → PVS1 Very Strong
PM2 supporting review Pathogenic
The variant is absent from gnomAD-Canada v1.0. Under the InSiGHT VCEP v2.0.0 PM2 rule, absence or extreme rarity (<1 in 50,000 alleles, i.e., <0.00002) in gnomAD v4 qualifies for PM2_Supporting. gnomAD v4.1 data were not available at the time of assessment; however, absence from ClinVar, gnomAD v2.1, and gnomAD-Canada is consistent with extreme rarity in the general population.
Absent from gnomAD-Canada v1.0Absent from ClinVargnomAD v4.1 data unavailable
Assessed · not applied
Pathogenic
PS2 VCEP PS2 requires de novo points based on confirmed parental testing.
PP1 VCEP PP1 requires segregation analysis with Bayes Likelihood Ratio thresholds.
PP4 VCEP PP4 requires MSI-H CRC/endometrial tumors or loss of MMR protein expression consistent with the variant location.
Benign
BA1 VCEP BA1 requires gnomAD v4 Grpmax filtering allele frequency ≥ 0.001.
BS1 VCEP BS1 requires gnomAD v4 Grpmax filtering allele frequency ≥ 0.0001 and < 0.001.
BS2 VCEP BS2 requires co-occurrence in trans with a known pathogenic MSH2 variant in a patient with CRC after age 45 without CMMRD features.
BS4 VCEP BS4 requires lack of co-segregation with disease in pedigrees with specified Bayes Likelihood Ratios.
BP5 VCEP BP5 requires evidence of MSS tumors, intact MMR protein expression inconsistent with the gene, or BRAF V600E/MLH1 methylation findings.
N/A · 17 PS1 · PS3 · PS4 · PM1 · PM4 · PM5 · PM6 · PP2 · PP3 · PP5 · BS3 · BP1 · BP2 · BP3 · BP4 · BP6 · BP7
Research & evidence
Population frequency
v4.1
This variant is absent from gnomAD v4.1.
v2.1
This variant is absent from gnomAD v2.1.
🇨🇦 CA
Absent from gnomAD-Canada v1.0.
Allele frequency by ancestry
three datasets · side by side
gnomAD Canada 🇨🇦
Absent · 0 / ?
0 hom
Not observed in any ancestry group.
ClinVar screenshot
ClinVar
This variant is absent from ClinVar.
SpliceAI screenshot
In silico
SpliceAI predicts no significant splice impact for this variant (max delta score = 0.09).
Functional / OncoKB screenshot
Functional Likely Oncogenic
OncoKB identified variant-specific curated literature and context relevant to functional review; biological-effect context: Likely Loss-of-function; curated oncogenicity label: Likely Oncogenic.
OncoKB ↗
COSMIC screenshot
COSMIC
Cancer hotspots screenshot
Cancer hotspots
Somatic evidence Not in COSMIC / hotspots
COSMIC
This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).
Hotspots
This variant does not lie in a statistically significant hotspot.
Sources & reference links
9Sources
CSpec VCEP
ClinVar
gnomAD v2.1
gnomAD v4.1
gnomAD-Canada
SpliceAI
OncoKB
COSMIC
Cancer hotspots
Triaged references · 5 PMIDs not cited in assessment
10946232 ↗ Structure and function of mismatch repair proteins. ONCOKB
11257106 ↗ Deficient DNA mismatch repair: a common etiologic factor for colon cancer. ONCOKB
15528792 ↗ Mutations associated with HNPCC predisposition -- Update of ICG-HNPCC/INSiGHT mutation database. ONCOKB
23391514 ↗ Structural, molecular and cellular functions of MSH2 and MSH6 during DNA mismatch repair, damage signaling and other noncanonical activities. ONCOKB
24362816 ↗ Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. ONCOKB